NextCure, Inc. Share Price
NXTCNextCure, Inc. Stock Performance
Open $13.10 | Prev. Close $13.17 | Circuit Range N/A |
Day Range $13.09 - $13.21 | Year Range $0.22 - $15.61 | Volume 4,250 |
Average Traded $13.12 |
NextCure, Inc. Share Price Chart
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NextCure, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
20-Jan-26 | $13.10 | $13.17 | +0.00% |
20-Jan-26 | $13.10 | $13.17 | +5.02% |
16-Jan-26 | $12.54 | $12.54 | -3.61% |
14-Jan-26 | $13.30 | $13.01 | -0.31% |
09-Jan-26 | $13.21 | $13.05 | -3.01% |
07-Jan-26 | $13.46 | $13.46 | -1.50% |
06-Jan-26 | $13.66 | $13.66 | +1.86% |